Document is current
Any future updates will be listed below
-
Authors
Zhang, Li
Fang, Wenfeng
Zhao, Yuanuan
Luo, Yongzhong
Yang, Runxiang
Huang, Yan
He, Zhiyong
Zhao, Hui
Li, Mingjun
Li, Kai
Song, Qibin
Du, Xiaobo
Sun, Yulan
Li, Wei
Xu, Fei
Wang, Zhiyu
Yang, Kunning
Li, Wenting
Li, Baiyong
Xia, Yu
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05184712 at ClinicalTrials.govDocuments that mention this clinical trial
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.8508
1348 Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR <sup>+</sup> NSCLC progressed on EGFR-TKI treatment
https://doi.org/10.1136/jitc-2025-sitc2025.1348
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-008037
- License Information
